Here’s what you should know:
1. Analysts believe Allergan will announce fourth quarter 2017 earnings of $0.83 per share Feb. 14, as well.
2. Analysts believe the company’s full-year earnings will increase approximately 13.98 percent, year over year.
3. Based on the projected earnings, 18 analysts awarded Allergan a “buy” rating and eight have deemed it a “hold.” No analysts issued a “sell” rating.
More articles on supply chain:
Healthcare-related lobbying hits $555M in 2017 — 6 statistics on lobbying in healthcare
Advanced Medical Group joins National Spine & Pain Centers — 4 things to know
Preoperative opioid users more likely to abuse opioids after TKA — 3 study insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
